Depomed, Inc. Announces Sweeping Interim Victory In Litigation Against IVAX Corporation

MENLO PARK, Calif.--(BUSINESS WIRE)--Depomed, Inc. (NASDAQ:DEPO) today announced a favorable “Markman” decision by Judge Charles Breyer of the United States District Court for the Northern District of California in Depomed’s patent infringement case against Ivax Corporation. Depomed sued Ivax for infringement of U.S. Patent Nos. 6,340,475 and 6,635,280 by Ivax’s extended release metformin hydrochloride tablets. The patents are held by Depomed and relate to the company’s AcuForm™ drug delivery technology. Depomed’s Glumetza™ product is covered by these patents.